VCM
FULC icon

Versant Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Versant Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-858
Closed -$6.58K – 2793
2026
Q1 		$6.58K Sell
858
-942
-52% -$8.74K ﹤0.01% 2305
2025
Q4 		$20.4K Hold
1,800
– – ﹤0.01% 1624
2025
Q3 		$16.6K Buy
+1,800
New +$13K ﹤0.01% 1692

Other funds holding FULC

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CP
Castleview Partners Dallas, Texas $228M AUM 19.85% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Versant Capital Management's FULC Position: Q2 2026 in Review

Versant Capital Management sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 858 shares — an estimated $6.58K sold.

Versant Capital Management first reported a position in FULC in Q3 2025 and held it in 3 quarters. The position peaked at $20.4K in Q4 2025. 12 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Versant Capital Management reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Versant Capital Management sold 858 Fulcrum Therapeutics shares in Q2 2026, an estimated $6.58K.
  • Versant Capital Management first reported a position in Fulcrum Therapeutics in Q3 2025 and held it in 3 quarters.
  • Versant Capital Management's Fulcrum Therapeutics position peaked at $20.4K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.